Laurie H. Sehn
Lymphoma specialist who wrote the definitive DLBCL review and helped establish polatuzumab and other new agents.
Overview
Laurie Sehn developed the revised International Prognostic Index for the rituximab era, led the BC Cancer population-based studies that showed R-CHOP's real-world impact, and was a lead investigator of the GO29365 trial establishing polatuzumab vedotin in relapsed DLBCL and of POLARIX. She authored the 2021 NEJM review of DLBCL and chairs lymphoma care in British Columbia.
| Title | Journal | Year |
|---|---|---|
| Diffuse large B-cell lymphoma | NEJM | 2021 |
| Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma | JCO | 2020 |
Pages like this
not linked directly; found by shared links- PersonHervé Tilly
Shares POLARIX, CD20, Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma and the tag lymphoma.
- PersonGilles Salles
Shares POLARIX, CD20, Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma and the tag lymphoma.
- PersonWyndham H. Wilson
Shares CD20, Diffuse large B-cell lymphoma and the tag lymphoma.
- PersonJoseph M. Connors
Shares BC Cancer, Antibody-drug conjugate (ADC) and the tag canada.
- TermInternational Prognostic Index (IPI)
Shares POLARIX, Diffuse large B-cell lymphoma.
- CompanyLEAH Labs
Shares CD20, Diffuse large B-cell lymphoma.
- PersonMichael Dickinson
Shares CD20, Diffuse large B-cell lymphoma and the tag lymphoma.
- PersonCatherine Thieblemont
Shares CD20, Diffuse large B-cell lymphoma and the tag lymphoma.